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Abstract
Individuals with psychosis are more likely than the general community to develop obesity and to die prematurely from
heart disease. Interventions to improve cardiovascular outcomes are best targeted at the earliest indicators of risk, at the
age they first emerge. We investigated which cardiometabolic risk indicators distinguished those with psychosis from the
general population, by age by gender, and whether obesity explained the pattern of observed differences. Data was
analyzed from an epidemiologically representative sample of 1,642 Australians with psychosis aged 18–64 years and a
national comparator sample of 8,866 controls aged 25–64 years from the general population. Cubic b-splines were used to
compare cross sectional age trends by gender for mean waist circumference, body mass index [BMI], blood pressure, fasting
blood glucose, triglycerides, LDL, HDL, and total cholesterol in our psychosis and control samples. At age 25 individuals with
psychosis had a significantly higher mean BMI, waist circumference, triglycerides, glucose [women only], and diastolic blood
pressure and significantly lower HDL-cholesterol than controls. With the exception of triglycerides at age 60+ in men, and
glucose in women at various ages, these differences were present at every age. Differences in BMI and waist circumference
between samples, although dramatic, could not explain all differences in diastolic blood pressure, HDL-cholesterol or
triglycerides but did explain differences in glucose. Psychosis has the hallmarks of insulin resistance by at least age 25. The
entire syndrome, not just weight, should be a focus of intervention to reduce mortality from cardiovascular disease.
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Introduction
All-cause mortality in individuals with schizophrenia is more
than twice that of the general population [1]. Life expectancy is
reduced by 10–25 years [2]. A common cause of that premature
death is coronary heart disease [3]. Interventions to improve
cardiovascular health should be implemented as early as possible
but the age when many potentially modifiable indicators of risk
first diverge in those with psychosis relative to the general
population is unknown. Weight gain is an early and common side
effect of antipsychotic drug treatment [4] and elevated body
weight and waist circumference are risk factors for insulin
resistance [5] and coronary heart disease [6]. How much of the
broader cardiometabolic risk profile associated with psychosis
across adulthood is driven by weight or central obesity is unknown.
Type 2 diabetes and heart disease both reflect the cumulative
effect of multiple risk factors. Typically, these risk factors have a
threshold above which they are considered clinically significant.
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However, multiple elevated but sub-threshold risk factors can also
be clinically significant and could be used to identify an emerging
risk factor profile. Left untreated that profile may hasten morbidity
and mortality but if identified early could be an effective target for
intervention.
The aims of this study were to determine 1] the age key
cardiometabolic risk indicators first diverge from the general
population in those with psychosis, 2] the pattern of cardiometa-
bolic risk indicators that characterizes psychosis across adulthood,
and 3] the extent to which elevated body mass index and waist
circumference explains the observed pattern of cardiometabolic
risk indicators associated with psychosis during adulthood. We
achieved aims 2] and 3] but aim 1] could not be determined
because the distinctive cardiometabolic profile that distinguished
psychosis was already present at age 25.
Materials and Methods
Ethics statement
The research protocol for the psychosis study was approved by
the University of Western Australia Human Research Ethics
Committee, the Human Research Ethics Committee at St
Vincent’s Health Melbourne, the Central Northern Adelaide
Health Services Ethics of Human Research Committee, the West
Moreton Health Service District Human Research Ethics Com-
mittee, the Melbourne Health Human Research Ethics Commit-
tee, the South Metropolitan Area Health Service Human
Research Ethics Committee, the Greater Western Area Health
Service Human Research Ethics Committee, the University of
Newcastle Human Research Ethics Committee and the Hunter
New England Research Ethics Committee.
Written informed consent was obtained from subjects after
complete description of the study. Individuals with psychosis
strongly endorse the importance of autonomous decision-making
[7] and psychotic symptoms (e.g., hallucinations, delusions) are not
significantly associated with diminished decisional capacity [8].
The survey excluded those with insufficient English or a
communication or cognitive impairment that would interfere with
a person’s capacity to give informed consent and to complete a
valid interview and those unavailable for screening or interview
due to residence in a nursing home or prison. Several safeguards
were also put in place to ensure that subjects were consented
appropriately. Interviewers, who judged the subject’s capacity to
consent, were all experienced mental health professionals.
Information about the study was presented in an enhanced visual
format to limit difficulties in comprehending or retaining
information and consent to participate was sought only at a time
when interviewers were confident that the subject’s psychosis did
not interfere with their capacity to give that consent. Anyone
deemed unable to provide informed consent was excluded from
the survey.
The research protocol for the general population survey was
approved by the Ethics Committee of the International Diabetes
Institute. Written informed consent was obtained after complete
description of the study to the subjects.
Samples
The psychosis sample is described in detail elsewhere [9]. In
brief, the Study of High Impact Psychosis [SHIP] is a population-
based cross-sectional study of psychosis. The target population was
defined by diagnosis, place of residence, age 18–64 years and
contact with public mental health services or relevant non-
government organizations. The study was conducted in 2010 at
seven sites across the five mainland Australian states. Sample
weights were devised based on age and site and were derived from
a census of those in contact with services at each site. Data
analyzed here are for the 1,642 participants aged 18–64 with a
diagnosis of ICD-10 [10] psychosis who also had cardiometabolic
data, n = 1,052 to 1,598. Psychosis diagnoses were schizophrenia
[53%, n = 857], bipolar disorder, mania [20%, n = 319], schizo-
affective disorder [16%, n = 293], depressive psychosis [5%,
n = 81] and delusional disorders or other non-organic psychoses
[6%, n = 92].
The general population sample is described in detail elsewhere
[11]. In brief, the Australian Diabetes, Obesity and Lifestyle study
[AusDiab] is a national population-based longitudinal study of
diabetes and cardiometabolic risk factors. The target population
was defined by place of residence and age 25+. The baseline
survey for AusDiab was conducted in 1999/2000 at six clusters
within each of the six states and the Northern Territory of
Australia. Sample weights were devised based on response rates
and coverage of the population within the sampling frame to
obtain nationally representative estimates. Data analyzed here are
for the 8,866 participants aged 25–64 years who completed the
baseline survey who also had cardiometabolic data, n = 8567 to
8864, and hereafter referred to as control data.
Measures
The Diagnostic Interview for Psychosis [12] was used to
diagnose psychosis and psychosis subtypes in SHIP. The physical
health assessment included measurement of waist circumference,
BMI, systolic and diastolic blood pressure, fasting plasma glucose,
total, LDL and HDL cholesterol and triglycerides in SHIP and
AusDiab [13,14]; all have thresholds to define at-risk status in the
general population [Table 1] and all metabolic assays were carried
out using standard enzymatic methods that were quality assured.
Drug treatment for psychosis, hypertension, elevated cholesterol,
hyperglycemia or diabetes was recorded based on self-report in
AusDiab and medication chart review in SHIP.
Statistical Analysis
Data analysis was undertaken using Stata v12.1. All parameter
estimation used sampling weights from each sample. The
prevalence of drug treatments between samples was compared
using a z-test. Pearson’s correlation coefficient was used to estimate
associations between variables. Cubic b-splines [15] for age in
years were generated using the Stata bsplines procedure and fitted
to each of the cardiometabolic risk indicators, separately by sex by
sample, yielding smoothed means across the age span. These
curves provide a relative unconstrained picture of differences in
each indicator over the lifespan but smooth minor variations due
to sampling. Substantial non-overlap of the confidence regions
[plotted as 61se] for the smoothed mean for each curve provides
an informal indication of the significant differences between the
psychosis and control samples for risk indicators at particular ages
or age ranges. The at-risk threshold for each indicator is included
on each plot. The age the average value for the psychosis sample
first exceeded each threshold was estimated from the fitted models.
We note when the estimated age was outside the range of observed
values and infer on that basis that the threshold was exceeded
before age 18. Age splines for blood pressure, lipids and glucose for
the psychosis sample were also fitted controlling for BMI and waist
circumference and estimated at the age and sex specific means of
these variables in controls to test if observed sample differences
were due to differences in mean BMI and central obesity.
The means for all risk indicators were compared within five age
bands (18–24; 25–34; 35–44; 45–54; 55–65) in those with affective
versus non-affective psychoses to test for potential heterogeneity in
Cardiometabolic Risk Indicators by Age and Gender
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our findings. Affective psychosis was defined as schizoaffective,
bipolar, mania, depressive psychosis and non-affective psychosis
was defined as schizophrenia, delusional & other non-organic
psychosis. These analyses were conducted separately for males and
females. Adjustment for multiple comparisons used the relatively
efficient Holm-Bonferroni method [16].
Results
Comparative pattern of cardiometabolic risk indicators
The same pattern of risk indicators distinguished psychosis at all
ages [Figures 1 and 2]: from at least age 25 individuals with
psychosis had significantly higher mean BMI, waist circumference,
diastolic blood pressure, triglycerides and glucose [women only]
and significantly lower HDL-c than controls [Table 2]. These
differences were observed at all ages, with the exception of
triglycerides at age 60+ in men [Figure 2d] and glucose which at
some ages was significantly worse in women with psychosis and at
some ages not [Figure 2e]. Systolic blood pressure did not differ
between samples at any age and, for men, neither did glucose.
Men with psychosis had significantly lower LDL-c from age 25
and significantly lower total cholesterol from age 35 than controls.
Women with psychosis had significantly lower LDL-c from age 46
and significantly lower total cholesterol before age 33 and after age
45 than controls. Non-HDL-c [total–HDL-c] may be elevated
when LDL-c is not but that was not the case here. The correlation
between non-HDL-c and total cholesterol in both samples was
.0.9.
Impact of adjustment for BMI and waist circumference
In those with psychosis the correlations of BMI and waist
circumference with other risk indicators ranged from 0.01 to 0.33
[0.18 to 0.42 in controls]. Adjusting risk indicator model estimates
in the psychosis sample to the mean BMI and waist circumference
of controls explained all of the observed elevation in glucose in
women with psychosis and drove other indicators that differed
significantly between samples towards the values observed in
controls but did not explain all the differences. For example, at the
mean age of the psychosis sample, 38.6 years for men and 40.7
years for women, adjustment for BMI and waist circumference
explained 22% of the difference in diastolic blood pressure in men
and 24% in women, 26% of the difference in HDL-c in men and
29% in women, and 32% of the difference in triglycerides in men
and 60% in women.
Age at which means exceeded the risk factor thresholds
in psychosis sample
The psychosis sample mean exceeded at-risk thresholds for
LDL-c at or below age 18, body mass and central obesity at or
below age 18–19, triglycerides at age 20 in women and age 34 in
men, HDL-c at age 25 in men and age 29 in women, fasting
plasma glucose at age 43 in women and age 48 in men, diastolic
hypertension at age 46 in women and age 53 in men and systolic
hypertension at age 55 in women and age 58 in men [Table 3].
Treatment for elevated cholesterol, hypertension or
diabetes
Between age 25–64 individuals with psychosis were 5.7 times
more likely to be treated for diabetes [9.1% versus 1.6%, z = 8.84
p,0.0001], 1.65 times more likely to be treated for hypertension
[12.26% versus 7.41%, z = 4.72 p,0.0001] and 2.8 times more
likely to be treated for elevated cholesterol [13.21% versus 4.72%,
z = 8.37 p,0.0001] than controls.
Table 1. Measures of obesity, dyslipidemia, diabetes and hypertension and associated risk thresholds.
Male Prevalence (95% CI) Raw N Female Prevalence (95% CI) Raw N























































































Key for Table 1:
M=Male; F = Female; 1 = estimated from fasting blood sample; All differences between the psychosis and the general population samples were significant (p,?001)
except overweight BMI in females (p,?01) and fasting blood glucose in females (p = 0?39).
doi:10.1371/journal.pone.0082606.t001
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Antipsychotic drug treatment
At the time of the psychosis survey 85% of the 1,642
participants had been prescribed antipsychotic medication in the
previous four weeks: 64% received second generation [atypical]
antipsychotic medication, 11% first generation [typical] antipsy-
chotic medication and 10.0% had been prescribed both. The most
commonly prescribed antipsychotic drugs were all atypicals:
risperidone 25%, quetiapine 25%, clozapine 21% and olanzapine
18%.
Tests for heterogeneity
Thirteen of the 90 comparisons undertaken in those with
affective versus non-affective psychosis were statistically significant
(p,.05) but only one (blood glucose in males aged 18–24) survived
within variable adjustment for multiple comparisons using the
relatively efficient Holm-Bonferroni method. Significant unadjust-
ed differences tended to be sporadic, occurring in only isolated age
groups inconsistently for males and females.
Discussion
Comparative pattern of cardiometabolic risk indicators
Insulin resistance is characterized by obesity, hypertension,
hyper-triglyceridemia, lowered HDL-c, sometimes elevated LDL-c
but more often elevated non-HDL-c, and ultimately in some cases
hyperglycemia and type 2 diabetes [17]. The pattern of
cardiometabolic risk indicators associated with psychosis here
may therefore reflect a propensity to develop insulin resistance.
Cross-sectional age trends for cardiometabolic risk indicators in
psychosis, by gender, have not previously been published. Once
seen, however, it is clear that individuals with psychosis are very
different from the general population from a very early age, at
least age 25, but how early for every indicator we cannot say.
Studies designed to estimate the national incidence of type 2
diabetes and characterize associated cardiometabolic risk factors,
like the AusDiab study that served as our control sample, do not
typically ascertain subjects prior to early adulthood.
Insulin resistance is a precursor of type 2 diabetes, it underlies
the metabolic syndrome and is a risk factor for coronary heart
disease [17]. Insulin resistance may therefore be a common
pathway for the elevated risk for all three conditions in those with
psychosis, and an important cause of their elevated cardiovascular
morbidity. Around half of all deaths in those with type 2 diabetes
are due to cardiovascular disease [18].
Impact of adjustment for BMI and waist circumference
Obesity is a common driver of insulin resistance [5]. The mean
body weight of the psychosis sample exceeded the overweight BMI
threshold at age 18. The mean waist circumference of the
psychosis sample exceeded the risk threshold before age 18 in
women and at age 19 in men. Nonetheless, BMI and waist
circumference could not explain all the observed differences in
diastolic blood pressure, HDL-c or triglycerides between samples.
Some of the weight differences between samples may be caused by
insulin resistance. Insulin resistance will increase appetite and
blunt satiety signals; excess circulating glucose will be converted to
fat by insulin. Insulin resistance in the heart could also have a
direct negative effect on heart function. Intervention to improve
the physical health of individuals with psychosis should therefore
target the entire insulin resistance syndrome, not just weight [19].
Figure 1. Smoothed means of body mass index [BMI], waist circumference, systolic and diastolic blood pressure by age in men and
women with psychosis [red] compared to general population controls [blue]. Shaded areas indicate 61 standard error of the mean.
Dashed lines indicate commonly used community thresholds of risk status [see Table 1].
doi:10.1371/journal.pone.0082606.g001
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Earliest age at which risk factor thresholds were
exceeded in psychosis sample
This could not be estimated for LDL-c because the sample
mean for those with psychosis already exceeded the at-risk
threshold at age 18. In contrast to those with psychosis, mean
BMI, HDL-c and diastolic blood pressure readings for those in the
general population never exceeded the thresholds that define
obesity, low HDL-c or hypertension.
Antipsychotic drug treatment effects
Psychosis onset occurred before age 25 in two-thirds of our
psychosis sample [9]. Duration of psychosis is therefore correlated
with age. Most individuals with psychosis were currently taking
antipsychotic drugs and their length of use is correlated with
duration of psychosis and therefore with age. If duration of illness/
antipsychotic drug treatment explained the cross-sectional age
trends reported here, risk would get worse with age relative to
controls. That’s not what we observed; differences actually
diminished a little with age. Controls get worse with age but
those with psychosis are also more likely to die with increasing age.
Any effect of duration of illness/treatment on emerging insulin
resistance must occur relatively early in the course of illness or
treatment, and in our psychosis sample by age 25. Experimental
studies of the very short-term [3 day] effects of olanzapine on
healthy controls have reported a pattern of findings very similar to
our own: lowered glucose tolerance, lowered HDL-c, elevated
triglycerides but not LDL-c or total cholesterol [20]. A review of
early cardiometabolic outcomes of treated psychosis described a
significant effect of antipsychotic drugs on BMI and waist
circumference, triglycerides, HDL-c and glucose and, unlike here,
LDL-c and total cholesterol [4]. However, those results are a
compilation of findings across multiple studies and many focused
only on weight change. The largest most comprehensive studies,
such as the EUFEST trial [21], did not discuss the changing
pattern of cardiometabolic indicators after initiation of antipsy-
chotic drug treatment but focused instead on differences in 1 year
Figure 2. Smoothed means of fasting blood total, LDL and HDL cholesterol, triglycerides and glucose by age in men and women
with psychosis [red] compared to general population controls [blue]. Shaded areas indicate 61 standard error of the mean. Dashed lines
indicate commonly used community thresholds of risk status [see Table 1].
doi:10.1371/journal.pone.0082606.g002
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outcomes for patients randomized to different drugs. Treatment
effects data beyond 1 year are so sparse due to the extremely high
rate of participant withdrawal that they cannot be considered
representative [6]. It is only recently that the annual incidence of
diagnosed diabetes in those treated with antipsychotic drugs has
been estimated using large population-based data [22].
Heterogeneity
The study did not identify any consistent differences in
cardiometabolic risk indicators between participants diagnosed
with an affective versus a non-affective psychosis. In some
instances this may reflect lack of power as the number of
participants was quite modest at the extremes of the age
distribution for some age bands. Elucidation of differences
Table 2. Age at which the mean for measures of obesity, dyslipidemia, diabetes and hypertension first exceeded standard risk
thresholds.
Male Female





Psychosis Controls Psychosis Controls
Dyslipidemia Cholesterol-LDL 1 -‘ -‘ 1= -‘ -‘
Obesity BMI overweight 2 18?0* 23?4{ 2 18?2 29?3
Obesity Waist circumference 3 19?1 38?0 1= -‘ 34?1
Dyslipidemia Triglycerides 4 20?1 41?2 4 33?7 62?3
Obesity BMI obese 5 29?1 -v 5 25?1 -v
Dyslipidemia Cholesterol-HDL 6 29?3 -‘ 3 24?4` -‘
Diabetes Glucose 7 43?5 45?0 6 47?7 59?4
Hypertension Diastolic BP 8 46?5 -v 7 53?5 -v
Hypertension Systolic BP 9 55?4 47?5 8 57?7 53?8
Dyslipidemia Cholesterol-total 10 -v 37?9 9 58?3 48?7
Key to Table 2:
{Estimate outside the age period of observation.
vAlways below threshold within the period of observation.
‘Always above threshold within the period of observation.
`HDL cholesterol is transiently above threshold at the extreme of the age range of observations (18–19?2).
*Occurs right at the edge of the age period of observation.
doi:10.1371/journal.pone.0082606.t002
Table 3. The age or age range when cardiometabolic risk indicators were significantly different in those with psychosis compared
with general population controls.
Domain Risk Indicator Males with psychosis 25–64 years Females with psychosis 25–64 years
Obesity Waist circumference Always worse Always worse
BMI Always worse Always worse
Dyslipidemia Cholesterol-Total Better after age 351 Better after age 452
Cholesterol-LDL Always better3 Comparable to , age 404
Cholesterol-HDL Always worse Always worse
Triglycerides Worse until ,605 Always worse
Hypertension Systolic BP Generally slightly better6 Generally slightly better7
Diastolic BP Always worse Always worse
Diabetes Glucose Generally comparable8 Generally comparable9
Key to Table 3:
1Mean is lower after age 33 but CIs do not overlap after age 35.
2Lower at all ages although between age 38 and 42 the difference is less than ?05 - lower than the accuracy of the assay. Before 33 and after 45 CIs do not overlap.
3CIs never actually coincide, but from 27–31 the gap between the lower bound of the general population sample and the upper bound of the psychosis sample is 0?0 to
one decimal place.
4After age 46 the CIs do not overlap. The psychosis sample mean is lower from age 40.
5Means for triglycerides in males from the psychosis and general population samples meet at 60. CIs overlap from age 57.
6Men from the general population sample have higher mean systolic blood pressure only between age 34 and 41. CIs always overlap, so the difference is not significant.
7Lower mean systolic blood pressure only between age 32 and 40 but CIs always overlap.
8Blood glucose means are higher from age 31 to 56 although CIs overlap during this period.
9Blood glucose means are higher up to age 60. CIs sometimes overlap, sometimes don’t during this period.
doi:10.1371/journal.pone.0082606.t003
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between individual psychosis diagnoses is likely to require larger
studies given the overall pattern of age and sex differences
observed here.
Antipsychotic drugs are not the only reason for the observed
propensity to insulin resistance in those with psychosis. An
association between diabetes and schizophrenia has been noted
for over a century and long before the advent of antipsychotic
drugs [23,24]. This is consistent with a higher prevalence of
abnormal glucose tolerance and increased visceral fat, both signs
of insulin resistance, in antipsychotic drug naı¨ve cases compared
with controls [25,26]. Some consider abnormal glucose tolerance a
risk equivalent to type 2 diabetes for coronary heart disease [27].
Risk for type 2 diabetes is then further increased by exposure to
antipsychotic drugs [28]. This varies by drug, with the greatest risk
observed in association with low potency first generation
antipsychotic drugs and with two second generation drugs,
olanzapine and clozapine [22]. This has led to recommendations
that certain drugs should not be first line treatment options [24].
Others have suggested low drug doses [29,30], extended [non-
daily] dosing [31,32] or drug switching [33] to limit adverse
effects.
Change in cardiometabolic risk indicators after commencement
of any antipsychotic drug should be closely monitored. Monitoring
guidelines have been developed and evaluated [34] but they have
had little impact on clinical practice [35]. This is an important
failure of care by those who prescribe antipsychotic drugs.
Mandated monitoring systems have been proposed [36] but this
alone won’t change the ‘‘scandal of premature mortality’’
associated with psychosis [37]. It is simply a first, necessary, step.
Effective ongoing medical management of treated psychosis is then
required [38].
Caveats and limitations
The lives and lifestyles of those with psychosis differ in many
ways from those in the general population. It therefore should not
be assumed that all differences in cardiometabolic risk indicators
can be attributed to either antipsychotic drugs or the unmeasured
risk factors that underlie the expression of psychosis, although both
play a role. Individuals with psychosis are more likely to smoke
cigarettes, have a poor diet and be physically inactive [39]. The
same caveats apply to these potential modifiers of risk as to the
effects of psychosis and antipsychotic drug treatment; they must
exert their effects early to generate the pattern of risk indicators
observed in the present study at age 25. Our results reflect the
current status of surveyed individuals given any past or current
drug treatment, irrespective of efficacy. Medication for psychosis,
hypertension, dyslipidemia or hyperglycemia could alter values on
cardiometabolic risk indicators, and may partly explain the
unexpectedly lower mean level of LDL, non-HDL and total
cholesterol in those with psychosis at some ages. The pattern of
dyslipidemia associated with psychosis here therefore requires
further investigation in other samples, including assessment of
ApoB, remnant like particles and small dense LDL-c which SHIP
did not measure. However, psychosis itself may also be associated
with an abnormal lipid profile [40].The present study was
conducted in one developed country [Australia] and the pattern
of observed risk given any current drug treatment will therefore
partly reflect national prescribing patterns and other factors that
determine access to health care. Replication is now needed in
other data sets from other countries to determine the degree of
international variation in observed patterns of multiple cardiome-
tabolic risk indicators by age in association with psychosis.
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